Relmada Therapeutics, Inc.

DB:4E2 Stock Report

Market Cap: €10.5m

Relmada Therapeutics Management

Management criteria checks 2/4

Relmada Therapeutics' CEO is Sergio Traversa, appointed in Apr 2012, has a tenure of 12.67 years. total yearly compensation is $4.78M, comprised of 14.7% salary and 85.3% bonuses, including company stock and options. directly owns 1.27% of the company’s shares, worth €133.50K. The average tenure of the management team and the board of directors is 4.9 years and 4.9 years respectively.

Key information

Sergio Traversa

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage14.7%
CEO tenure12.7yrs
CEO ownership1.3%
Management average tenure4.9yrs
Board average tenure4.9yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Sergio Traversa's remuneration changed compared to Relmada Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$86m

Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$94m

Dec 31 2023US$5mUS$701k

-US$99m

Sep 30 2023n/an/a

-US$112m

Jun 30 2023n/an/a

-US$129m

Mar 31 2023n/an/a

-US$144m

Dec 31 2022US$3mUS$668k

-US$157m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$157m

Mar 31 2022n/an/a

-US$143m

Dec 31 2021US$36mUS$630k

-US$126m

Sep 30 2021n/an/a

-US$112m

Jun 30 2021n/an/a

-US$86m

Mar 31 2021n/an/a

-US$71m

Dec 31 2020US$900kUS$600k

-US$59m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$16mUS$214k

-US$15m

Sep 30 2019n/an/a

-US$18m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018n/an/a

-US$17m

Sep 30 2018n/an/a

-US$11m

Jun 30 2018US$975kUS$376k

-US$9m

Compensation vs Market: Sergio's total compensation ($USD4.78M) is above average for companies of similar size in the German market ($USD468.04K).

Compensation vs Earnings: Sergio's compensation has increased whilst the company is unprofitable.

CEO

Sergio Traversa (64 yo)

12.7yrs

Tenure

US$4,778,944

Compensation

Dr. Sergio Traversa, PharmD, MBA has been the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. since April 18, 2012. Dr. Traversa served as Interim Chief Financial Officer at Relmada Th...

Leadership Team

NamePositionTenureCompensationOwnership
Sergio Traversa
CEO & Director12.7yrsUS$4.78m1.27%
€ 133.5k
Maged Shenouda
Chief Financial Officer4.9yrsUS$2.34m0.29%
€ 30.7k
Charles Ence
Chief Accounting & Compliance Officer4.9yrsUS$2.33m0.13%
€ 13.5k
Paolo Manfredi
Chief Scientific Officer4.2yrsno datano data
Gina DiGuglielmo
VP & Head of Clinical Operations5.7yrsno datano data
Marco Pappagallo
Chief Clinical Officer4.2yrsno datano data
John Hixon
Head of Commercial2.4yrsno datano data
Andrew Cutler
Senior Clinical Development Advisorno datano datano data
Richard Mangano
Consultant7.7yrsno datano data

4.9yrs

Average Tenure

63yo

Average Age

Experienced Management: 4E2's management team is considered experienced (4.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sergio Traversa
CEO & Director12.7yrsUS$4.78m1.27%
€ 133.5k
Maged Shenouda
Chief Financial Officer4.9yrsUS$2.34m0.29%
€ 30.7k
Charles Casamento
Independent Chairman of the Board9.4yrsUS$674.90k0%
€ 0
Stephen Stahl
Member of Scientific Advisory Board4.9yrsno datano data
Maurizio Fava
Member of Scientific Advisory Board7.5yrsno datano data
Fabiana Fedeli
Independent Director1.9yrsUS$1.33m0%
€ 0
Paul Kelly
Director9.1yrsUS$1.67m0.70%
€ 73.8k
Charles Inturrisi
Member of Scientific Advisory Boardno datano datano data
John Glasspool
Independent Director5yrsUS$604.77kno data
Luca Pani
Member of Scientific Advisory Board4.9yrsno datano data
Dan Iosifescu
Member of Scientific Advisory Board4.9yrsno datano data
Sanjay Mathew
Member of Scientific Advisory Board4.9yrsno datano data

4.9yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 4E2's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 02:42
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Relmada Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerAegis Capital Corporation
Maxim JacobsEdison Investment Research
Yatin SunejaGuggenheim Securities, LLC